By combining an in-house created, advanced blood analysis technology with unprecedented access to global health databases and world-leading medical research, Nightingale Health goes beyond individual biomarkers by providing a direct connection to disease risks and a prediction of future health.
1 / 5
A blood sample taken at home or at a labRead more
2 / 5
Sample analyzed by our proprietary blood analysis technologyRead more
3 / 5
Analysis reveals hundreds of moleculesRead more
4 / 5
Molecules are compared to the health data from hundreds of thousands of individualsRead more
5 / 5
Results are provided in an understandable and actionable format empowering people to live healthier livesRead more
A blood sample is taken at home or lab
Nightingale Health’s technology requires only one blood sample.
Our technology can utilize venous blood samples collected as a part of routine healthcare or finger prick samples collected at home.
Venous samples do not require any special processing and can be sent to us using existing laboratory logistics. Since a very low amount of blood is needed, a sample taken for other purposes can be split and part of it forwarded for our analysis, minimizing the burden for patients.
Finger prick samples can be provided to us utilizing a self-collection device included in our home-kit. The self-collection device collects a standardized amount of blood. The device automatically separates the plasma from the collected blood and stores it as a dried sample, allowing the sample to be sent back to our laboratory via regular mail.
Sample is analyzed with Nightingale Health’s proprietary technologyWe analyze each sample with our proprietary blood testing technology globally available only from Nightingale Health. The technology is created completely in-house and utilizes nuclear magnetic resonance spectroscopy (NMR).
The fully automated process begins with an NMR measurement that creates spectral data of the sample. Our proprietary purpose build algorithms and software processes the spectral data into concentrations of readable molecules in the case of venous samples (millimoles per litre or “mmol/L”) or, in the case of finger prick samples, into molecular input data for the calculation of Nightingale Health’s next-generation health metrics. Together, the full automation, extensive capture of molecular data, clinical laboratory level quality control, and high-throughput processing makes our technology revolutional.
Analysis reveals hundreds of molecules
Nightingale’s analysis produces up to 250 times more molecular health data than provided by a regular blood test, all from one sample. This health information provides a comprehensive picture of human metabolism. The same set of results analyzed with traditional methods would require several separate blood tests and samples.
We’ve already analyzed over a million samples and are analyzing samples with continuously increasing numbers. Our technology produces comprehensive, highly accurate, and repeatable biomarker results quickly and at a low cost on a mass scale. Nightingale's laboratories operate under a certified quality management system in accordance with EN ISO 13485 and SFS-EN ISO/IEC 17025, and all blood samples are measured with a CE-marked IVD device. These regulatory approvals have enabled Nightingale Health’s analysis to be brought to use in healthcare settings.
Our analysis measures biomarkers such as amino acids, apolipoproteins, cholesterols, fatty acids, fatty acid ratios, glycolysis metabolites, inflammation, ketone bodies, lipoprotein particle concentrations, lipoprotein particle sizes, lipoprotein subclasses, triglycerides, and more.
If you are interested in using our technology for medical research, visit our website for researchers here.
Risk prediction algorithms built based on hundreds of thousands of individualsOnce the molecular input data of a person’s metabolic profile has been created, we utilize our proprietary algorithms to go beyond biomarkers by providing a direct connection to disease risks and prediction of future health.
These algorithms utilize real-life data to directly link the measurement results to the risk of falling ill with the diseases that most commonly shorten active life. To date, we have analyzed hundreds of thousands of blood samples from international biobanks with our technology. Those analysis results have been compared using scientific data analyses to the medical records of the biobank participants. These analyses have found many diseases that are associated with the results of our blood test and form the basis for the calculation of our next-generation health metrics.
The blood samples in the biobank studies are from up to 10 years ago. Since it is known what happened in those 10 years to the people who gave the samples, Nightingale Health’s technology could find out what common factors were present in the blood analysis results of the people who were still healthy but became ill during that follow-up period. Therefore, if we could now go back to the time the blood samples were taken, Nightingale Health would be able to identify in advance many of the people who would develop diseases in the next 10 years. Thus, by comparing an individual’s blood test results to the hundreds of thousands of samples Nightingale Health has already analyzed, we are able to predict how long an individual is likely to live healthy.
Understandable and actionable results via mobile app to empower individuals towards lifelong health.
Nightingale delivers the analysis results to consumers via our mobile app. The bundled health metrics and risk predictions are easy to understand and empower the individual to take action toward better health. Additionally, the app includes science-based advice on improving health with daily lifestyle choices.We have also built APIs that allow the results to be embedded into the apps of our partners. This allows the widespread use of the analysis results, also with partners’ own branding.
Nightingale is committed to achieving high quality in all its services. Quality and compliance with all applicable regulatory and customer requirements underline all our operations.
Certified quality management system
Nightingale Health operates under a certified quality management system in accordance with EN ISO 13485 (certified by DEKRA Certification B.V.). All operations and processes involved in the analysis service fall under the QMS.
Nightingale Health measures all blood samples with a CE-marked IVD device. This means that samples are measured using the CE-marked IVD device that is used for the measurement of clinical samples for customers requiring the most stringent quality assurance.
External quality assurance
Nightingale Health participates in UK NEQAS, WEQAS and Labquality external quality assurance programmes to monitor the measurement quality between Nightingale Health and other laboratories.
Certified information security management system
Nightingale Health has an ISO/IEC 27001 certified Information Security Management System. ISO/IEC 27001 is a globally recognized standard for information security management systems. With the Information Security Management System, Nightingale Health ensures that it maintains appropriate measures to secure data, products, and services. This information security certification also shows Nightingale Health's overall dedication to data security and commitment to continuously develop information security within the company.
Nightingale's laboratories operate under a certified quality management system in accordance with EN ISO 13485 and SFS-EN ISO/IEC 17025, and blood samples are measured with a CE-marked IVD device. Analytical performance for the CE-marked analytes is demonstrated according to CLIA's US FDA recognized consensus standards, and the CE-marked analytes are calibrated to the standard reference materials, if available, provided by the National Institute of Standards and Technology (NIST).